Sydney Jennings

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.

Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.

Your daily dose of the clinical news you may have missed.

The VITESSE trial met its primary endpoint, with the VIASKIN Peanut patch improving desensitization versus placebo in peanut-allergic children aged 4 to 7 years.

Phase 2b REZOLVE-AA trial results show rezpegaldesleukin reduced SALT scores versus placebo in severe alopecia areata, supporting Phase 3 development.

Gilead's ARTISTRY-2 trial shows a promising single-tablet HIV treatment regimen is noninferior to standard therapy, expanding options for virologically suppressed adults.

Your daily dose of the clinical news you may have missed.

Dr Hatfield shares a case of a patient living in shared housing who was concerned about her housemates seeing her PrEP medication.

Dupilumab shows superior 2-year drug survival rates in atopic dermatitis compared to other biologics and JAK inhibitors, highlighting its effectiveness in treatment persistence.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Gepotidacin becomes the first new oral antibiotic for gonorrhea in over 30 years, offering hope for effective treatment options.

Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.

Your daily dose of the clinical news you may have missed.

Intranasal epinephrine emerges as a safe, effective alternative for anaphylaxis treatment, offering ease of use and promising real-world results.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

A cohort study of 531 851 primary care patients found routine AUDIT-C alcohol screening scores predict 8-year all-cause mortality, with strongest effects in younger adults.

Your daily dose of the clinical news you may have missed.

A new rapid HIV test accurately differentiates vaccine-induced false positives from active HIV-1 infection, potentially improving diagnostics and vaccine trials.

A new meta-analysis reveals monoclonal antibodies, including dupilumab, outperform placebo in treating moderate-to-severe atopic dermatitis.

Your daily dose of the clinical news you may have missed.

A multinational survey of HS specialists in Europe found that 81% prescribe antibiotics despite expecting poor response and 79% favor earlier biologic initiation.

Your daily dose of the clinical news you may have missed.

Topical roflumilast 0.3% improved IGA, PASI, itch, and symptom scores in plaque psoriasis with a safety profile comparable to vehicle.

Highlights include widespread lack of structured menopause education in primary care residency programs, sleep benefits of elinzanetant, and more.